Zoeken
Urologie

Klinische studies dienst urologie

Bekijk het overzicht van de studies die op dit moment aangeboden kunnen worden aan patiënten met urologische tumoren en andere urologische problemen.
Op deze pagina

Blaas- en urinewegentumoren

EFFORT Trial

Phase II prospective trial to evaluate the impact of 18FFDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and adapting the treatment accordingly.

TAR-210 MoonRISe-1

 Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer

  • Inclusion criteria: IR-NMBC papillary disease Ta LG/G1 – recurrent OR Ta LG/G1 - primary and multifocal or primary and ≥ 3cm OR Ta G2 - primary or recurrent. With ≥ 1 of the following risk factors: Multiple Ta LG tumors, Solitary LG tumor > 3cm, Early recurrence of LG tumor (<1Y), Frequent recurrence (>1 per Y) and/or Recurrence after prior intravesical chemotherapy Local site Principal.
  • Exclusion criteria: Received intravesical chemotherapy within 6 months of current diagnosis, received prior intravesical treatment with immunotherapy including BCG within 2 years prior to randomization, received prior treatment with an FGFR inhibitor.
  • Investigator: Prof. Dr. Steven Joniau 
  • Sub-investigator (Urology): Dr. Loïc Baekelandt 
  • More information: NCT06319820

 

Blaaspijnsyndroom

Er zijn momenteel geen studies beschikbaar.

 

Niertumoren

Er zijn momenteel geen studies beschikbaar.

 

Overactieve blaas

CARE Studie

Continence Achieved through Recording of Electrophysiology (CARE) Study: A Prospective Study to Evaluate the Safety and Feasibility of using the Closed Loop Medical Sacral Nerve Stimulation System (the Repose™ System) in the treatment of Symptoms of Overactive Bladder

  • Inclusie criteria: oa >= 18 jaar, Chronische OAB (> 12 maanden), Urgentie incontinentie, Onder stabiele OAB medicatie, Restblaasvolume <150cc, Geschikte kandidaat om een SNS-procedure te ondergaan
  • Exclusie criteria: oa Hoofddiagnose stressincontinentie, Neurogene blaas, Interstitiële cystitis, Urinewegobstructie of urethrastrictuur, Botox injecties voor OAB (<9 maanden geleden)
  • Local site Principal Investigator: prof. dr. Frank Van der Aa
  • Sub-investigator: dr. Lucas Landen
  • More information: ACTRN12622000999730

 

Penistumoren

BELPEN

Magnetic detection of sentinel lymph nodes in patients with penile cancer from Belgium

  • Inclusion criteria: Penile cancer, suspected squamous cell carcinoma, ≥ pT1b G2 N0 M0, surgical intervention with a dynamic sentinel node biopsy procedure (using standard intradermal nanocolloid) being part of the surgical plan
  • Local site Principal Investigator (Urology): prof. dr. Maarten Albersen
  • Sub-investigator (Nuclear Medicine): prof. dr. Karolien Goffin
  • More information: dr. Laura Elst (Phd): 016 34 73 58

 

Prostaattumoren

EvoPAR-Prostate01

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of novel PARP inhibitor AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer

  • Inclusion criteria: mCSPC (adenocarcinoma), de novo or recurrent, with ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion on conventional imaging (bone scan, CT/MRI). ADT with a GnRH analogue < 4 months with no radiographic evidence of disease progression or rising PSA levels. Participant must remain on ADT and be a candidate for treatment with an NHA (Abi, Daro, Enza).
  • Local site Principal Investigator: prof. dr. Steven Joniau 
  • Sub-investigator (Urology): dr. Alexander Giesen 
  • More information: NCT06120491

ARASTEP

A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

  • Inclusion criteria: High-risk BCR after RP followed by adjuvant RT or salvage RT or after RP in participants who are unfit for adjuvant RT or salvage RT or after Primary RT.  nmCSPC (adenocarcinoma) according to conventional imaging. PSADT < 12months.
  • Local site Principal Investigator: prof. dr. Steven Joniau.
  • Sub-investigator (Urology): dr. Alexander Giesen
  • More information: NCT05794906.

 

Testistumoren

Er zijn momenteel geen studies beschikbaar.

 

Urinaire incontinentie

COLD INDUCED

Diagnostic tool and therapeutic strategy for acute cold-induced urgency (ACIU) part 2: optimizing the protocol

  • Inclusion criteria: All patients with an overactive bladder for which a Urodynamic investigation is scheduled. Note that patients with prior pelvic floor surgery, neurological disorder or peripheral neuropathy are excluded from the study.
  • Local site Principal Investigator: prof. dr. Wouter Everaerts
  • Sub-investigator: prof. dr. Frank Van der Aa
  • More information: dr. Lucas Landen

 

Urinaire retentie

Er zijn momenteel geen studies beschikbaar.

 

Urineweg-infecties

MINUS Trial

Multicentric study on Infections of the Urinary tract after Stent removal

  • Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
  • Local site Principal Investigator: dr. Carl Van Haute
  • Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
  • More information: NCT05329883
Laatste aanpassing: 12 november 2024